Abstract 2344
Background
The Economist Intelligence Unit takes a strategic approach to understand the impact of policy on lung cancer. Recommendations from our research, sponsored by MSD, will assist countries to improve systemic responses because outcomes remain poor and costs remain high despite scientific progress.
Methods
Our research centres on 13 countries: Austria, Belgium, Finland, France, Germany, Greece, Netherlands, Norway, Poland, Romania, Spain, Sweden, and the UK. Our literature review drew evidence from internationally-recognised sources and falls into 5 domains operationalised by 17 indicators assessing performance across the entire patient journey. After consultation with European experts, we populated our scorecard comparing policy and practice, examining service delivery, systems, access, financing and governance. Examination of preliminary findings in country workshops with clinicians, patient organisations and other key stakeholders enabled us to obtain nuanced information providing a clearer grasp on care than obtained from desk research alone.
Results
While patches of good practice exist, no country scores highly across all of our measurements. All but one country has a national cancer control plan: 75% are over five years old and do not incorporate recent oncological innovations. Clinical guidelines lack details on accelerating suspected lung cancer patients for diagnosis, referral pathways to secondary/tertiary care, supportive/palliative care, shared decision-making and psychological support within a specified time. Cancer registries exist in each country, yet clinicians report that clinically-focused cancer registries could house important information. Only 5 countries reimburse all four commonly used biomarkers for lung cancer.
Conclusions
Room for improvement in lung cancer policy exists across all the countries and domains we have studied. Our workshops ensured we focus on the most important opportunities for improving the delivery of lung cancer care relevant for each country. Now, based on the recommendations coming out of the research and agreed upon by stakeholders, we are in the policy development phase of our work where our goal is to assist policymakers improve care for people living with lung cancer in Europe.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract